Tribenoside

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tribenoside
Accession Number
DB13227
Type
Small Molecule
Groups
Experimental
Description

Anti-inflammatory agent used in edema of extremities, varicose veins & phlebitis.

Structure
Thumb
Synonyms
  • TBGF
  • Tribenosido
  • Tribenosidum
External IDs
21401-BA / Ba 21401 / BG-356
Categories
UNII
Z7N0Y673NU
CAS number
10310-32-4
Weight
Average: 478.585
Monoisotopic: 478.235538815
Chemical Formula
C29H34O6
InChI Key
ULLNJSBQMBKOJH-VIVFLBMVSA-N
InChI
InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25-,26-,27-,28-,29?/m1/s1
IUPAC Name
(3R,4R,5R)-4-(benzyloxy)-5-[(1R)-1,2-bis(benzyloxy)ethyl]-2-ethoxyoxolan-3-ol
SMILES
CCOC1O[C@H]([C@@H](COCC2=CC=CC=C2)OCC2=CC=CC=C2)[C@H](OCC2=CC=CC=C2)[C@H]1O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tribenoside.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tribenoside is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tribenoside is combined with 5-androstenedione.Experimental, Illicit
AbciximabTribenoside may increase the anticoagulant activities of Abciximab.Approved
AcebutololTribenoside may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tribenoside.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tribenoside is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTribenoside may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tribenoside.Approved, Vet Approved
AclarubicinTribenoside may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tribenoside.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tribenoside.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Aldosterone.Experimental, Investigational
AldoxorubicinTribenoside may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tribenoside is combined with Alendronic acid.Approved
AliskirenTribenoside may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tribenoside is combined with Alminoprofen.Experimental
AlprenololTribenoside may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tribenoside.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Amcinonide.Approved
AmikacinTribenoside may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideTribenoside may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinTribenoside may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTribenoside may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tribenoside.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tribenoside is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tribenoside is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tribenoside.Investigational
AnnamycinTribenoside may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tribenoside.Approved, Investigational
Antithrombin III humanTribenoside may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTribenoside may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Tribenoside.Investigational
ApramycinTribenoside may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tribenoside.Approved, Investigational
ArbekacinTribenoside may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTribenoside may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTribenoside may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTribenoside may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Atamestane.Investigational
AtenololTribenoside may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tribenoside.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tribenoside.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Tribenoside is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tribenoside.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tribenoside.Investigational
BalsalazideTribenoside may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminTribenoside may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTribenoside may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTribenoside may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Tribenoside is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tribenoside.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tribenoside.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Tribenoside is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tribenoside.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Betamethasone.Approved, Vet Approved
BetaxololTribenoside may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tribenoside.Approved, Investigational
BevantololTribenoside may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Tribenoside is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tribenoside.Approved, Investigational
BisoprololTribenoside may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTribenoside may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTribenoside may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tribenoside.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tribenoside.Investigational
BucindololTribenoside may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tribenoside is combined with Bufexamac.Approved, Experimental
BufuralolTribenoside may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tribenoside.Approved
BupranololTribenoside may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tribenoside.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tribenoside.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tribenoside is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tribenoside.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tribenoside.Approved, Vet Approved, Withdrawn
CarteololTribenoside may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTribenoside may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tribenoside.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tribenoside is combined with Celecoxib.Approved, Investigational
CeliprololTribenoside may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTribenoside may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tribenoside.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tribenoside.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tribenoside.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tribenoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tribenoside.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Cilazapril.Approved
CinoxacinTribenoside may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidTribenoside may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Tribenoside.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tribenoside.Vet Approved
CloranololTribenoside may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Tribenoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tribenoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Tribenoside.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tribenoside.Experimental
CyclosporineTribenoside may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTribenoside may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTribenoside may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTribenoside may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTribenoside may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinTribenoside may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tribenoside is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tribenoside is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Delapril.Experimental
DesirudinTribenoside may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tribenoside.Approved, Investigational
DextranTribenoside may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinTribenoside may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Tribenoside is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tribenoside.Approved, Vet Approved
DicoumarolTribenoside may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tribenoside.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tribenoside.Approved
DihydrostreptomycinTribenoside may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tribenoside.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tribenoside.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tribenoside.Approved
DoxorubicinTribenoside may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTribenoside may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Tribenoside.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tribenoside.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Tribenoside.Investigational
Edetic AcidTribenoside may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTribenoside may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Tribenoside is combined with Enalaprilat.Approved
EnoxacinTribenoside may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTribenoside may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tribenoside.Experimental
EpanololTribenoside may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Tribenoside.Approved
EpirubicinTribenoside may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tribenoside.Experimental
EplerenoneTribenoside may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tribenoside.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tribenoside.Approved
EquileninThe risk or severity of adverse effects can be increased when Tribenoside is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tribenoside is combined with Equilin.Approved
EsmololTribenoside may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tribenoside.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tribenoside.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTribenoside may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tribenoside is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tribenoside is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tribenoside.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Tribenoside is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Tribenoside.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Tribenoside.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Tribenoside.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tribenoside.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tribenoside.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tribenoside.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tribenoside.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Feprazone.Experimental
Ferulic acidTribenoside may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tribenoside.Approved, Investigational
FleroxacinTribenoside may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tribenoside.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fludrocortisone.Approved, Investigational
FluindioneTribenoside may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTribenoside may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Tribenoside.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tribenoside is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tribenoside.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tribenoside.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tribenoside.Approved, Nutraceutical, Vet Approved
FondaparinuxTribenoside may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumTribenoside may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tribenoside.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fosinopril.Approved
FramycetinTribenoside may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tribenoside.Approved, Vet Approved
GabexateTribenoside may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTribenoside may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTribenoside may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tribenoside.Approved, Withdrawn
GemifloxacinTribenoside may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTribenoside may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTribenoside may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATribenoside may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Tribenoside may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinTribenoside may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Tribenoside is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tribenoside is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tribenoside is combined with HE3286.Investigational
HeparinTribenoside may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Tribenoside.Investigational
HydralazineTribenoside may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tribenoside.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tribenoside.Approved, Investigational
Hygromycin BTribenoside may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tribenoside.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Tribenoside.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tribenoside.Approved, Investigational
IdarubicinTribenoside may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxTribenoside may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tribenoside.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tribenoside.Approved
IndenololTribenoside may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Tribenoside.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tribenoside.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tribenoside.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tribenoside.Approved, Investigational
IsepamicinTribenoside may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tribenoside.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tribenoside is combined with Istaroxime.Investigational
KanamycinTribenoside may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tribenoside.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tribenoside.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tribenoside.Approved
LabetalolTribenoside may decrease the antihypertensive activities of Labetalol.Approved
LandiololTribenoside may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tribenoside.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tribenoside.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tribenoside.Approved, Investigational
LepirudinTribenoside may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTribenoside may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololTribenoside may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTribenoside may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tribenoside.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tribenoside.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tribenoside.Approved
LonazolacThe risk or severity of adverse effects can be increased when Tribenoside is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tribenoside.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tribenoside.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Tribenoside is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tribenoside.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tribenoside.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tribenoside is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tribenoside.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tribenoside.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tribenoside.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tribenoside is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tribenoside.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tribenoside.Approved
MelagatranTribenoside may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tribenoside is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tribenoside.Approved, Vet Approved
MepindololTribenoside may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineTribenoside may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tribenoside.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tribenoside.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tribenoside.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTribenoside may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tribenoside.Approved
MetoprololTribenoside may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTribenoside may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinTribenoside may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tribenoside.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tribenoside.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tribenoside.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tribenoside.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tribenoside.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tribenoside.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Nabumetone.Approved
NadololTribenoside may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTribenoside may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTribenoside may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tribenoside.Approved
Nalidixic AcidTribenoside may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tribenoside.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Tribenoside is combined with NCX 1022.Investigational
NeamineTribenoside may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTribenoside may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTribenoside may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTribenoside may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tribenoside.Approved, Investigational
NetilmicinTribenoside may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tribenoside.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tribenoside.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tribenoside.Investigational
NorfloxacinTribenoside may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tribenoside.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tribenoside.Approved
OlsalazineTribenoside may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Tribenoside is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Tribenoside is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Tribenoside.Vet Approved
OtamixabanTribenoside may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tribenoside.Approved
Oxolinic acidTribenoside may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTribenoside may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tribenoside.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tribenoside is combined with Parecoxib.Approved
ParomomycinTribenoside may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Tribenoside.Approved, Investigational
PazufloxacinTribenoside may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTribenoside may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTribenoside may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTribenoside may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTribenoside may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Perindopril.Approved
PhenindioneTribenoside may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTribenoside may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tribenoside.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tribenoside.Approved, Investigational
PindololTribenoside may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidTribenoside may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinTribenoside may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tribenoside.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tribenoside.Approved, Investigational
Piromidic acidTribenoside may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tribenoside.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorTribenoside may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTribenoside may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTribenoside may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tribenoside.Approved
PractololTribenoside may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tribenoside.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Tribenoside can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Tribenoside is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tribenoside.Approved, Investigational
PropranololTribenoside may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tribenoside.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tribenoside.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tribenoside.Vet Approved
Protein CTribenoside may increase the anticoagulant activities of Protein C.Approved
Protein S humanTribenoside may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTribenoside may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTribenoside may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tribenoside.Investigational
PuromycinTribenoside may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tribenoside.Approved
RamiprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Tribenoside is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tribenoside.Approved, Experimental, Investigational
ReviparinTribenoside may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTribenoside may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Risedronate.Approved, Investigational
RivaroxabanTribenoside may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tribenoside is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinTribenoside may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTribenoside may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTribenoside may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tribenoside.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tribenoside.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tribenoside.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tribenoside.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tribenoside.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tribenoside.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tribenoside.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Tribenoside.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tribenoside.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tribenoside.Investigational
SisomicinTribenoside may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTribenoside may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Tribenoside.Approved
SotalolTribenoside may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTribenoside may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTribenoside may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTribenoside may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Spirapril.Approved
SpironolactoneTribenoside may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tribenoside.Investigational
StreptomycinTribenoside may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTribenoside may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tribenoside.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tribenoside.Approved, Investigational
SulodexideTribenoside may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tribenoside.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tribenoside.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Suxibuzone.Experimental
TacrolimusTribenoside may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tribenoside.Approved
TalinololTribenoside may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tribenoside.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tribenoside.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tribenoside.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tribenoside is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tribenoside.Approved, Investigational
TemafloxacinTribenoside may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tribenoside is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tribenoside.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Tribenoside.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tribenoside.Approved
TertatololTribenoside may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tribenoside.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Tribenoside is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTribenoside may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Tribenoside.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tribenoside is combined with Tixocortol.Approved, Withdrawn
TobramycinTribenoside may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tribenoside.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tribenoside.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tribenoside.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Tribenoside.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tribenoside.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tribenoside.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTribenoside may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tribenoside.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Tribenoside.Investigational
TrovafloxacinTribenoside may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTribenoside may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Tribenoside is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tribenoside.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Tribenoside is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinTribenoside may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tribenoside.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tribenoside.Approved
WarfarinTribenoside may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTribenoside may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tribenoside.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tribenoside.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Tribenoside is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Tribenoside is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tribenoside.Withdrawn
Zoptarelin doxorubicinTribenoside may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTribenoside may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
169970
ChEBI
91780
ChEMBL
CHEMBL3301681
Wikipedia
Tribenoside
ATC Codes
C05CX01 — TribenosideC05AX05 — Tribenoside

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00325 mg/mLALOGPS
logP4.13ALOGPS
logP5.17ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)12.36ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.38 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity133.51 m3·mol-1ChemAxon
Polarizability52.51 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
Benzylethers / Monosaccharides / Tetrahydrofurans / Secondary alcohols / Oxacyclic compounds / Dialkyl ethers / Acetals / Hydrocarbon derivatives
Substituents
O-glycosyl compound / Benzylether / Benzenoid / Monosaccharide / Monocyclic benzene moiety / Tetrahydrofuran / Secondary alcohol / Oxacycle / Organoheterocyclic compound / Ether
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:38 / Updated on May 02, 2018 00:30